Bharat Biotech weighs $500 Million IPO as India’s biotech sector eyes capital market test

Bharat Biotech is reportedly evaluating a potential $500 million IPO, which could rank among India’s largest biotechnology listings in recent years. Deliberations remain preliminary, with timing and structure contingent on market conditions and investor demand.

Hyderabad-based Bharat Biotech is exploring a public market debut that could raise approximately USD 500 million, according to people familiar with the matter. Discussions are understood to be at an early stage, and the company has not made a formal announcement. Key parameters including valuation, offer structure and launch timeline remain subject to internal review and prevailing equity market dynamics.

Founded in 1996, Bharat Biotech is a privately held vaccine manufacturer with a diversified portfolio spanning hepatitis B, typhoid, rotavirus, Japanese encephalitis and influenza. The company gained international visibility during the COVID-19 pandemic and currently exports vaccines to more than 100 countries, positioning it within global immunisation supply chains.

A listing of this magnitude would test investor appetite for research-driven healthcare businesses at a time when India’s IPO market has become more selective. While long-term demand for vaccines and biologics remains supported by public health priorities and global disease surveillance, equity volatility and tighter capital allocation standards have heightened scrutiny around pricing and fundamentals.

For Bharat Biotech, accessing public capital could support expansion in R&D, manufacturing scale-up and pipeline development, while also introducing greater financial transparency and regulatory oversight. Institutional investors are likely to assess revenue durability beyond pandemic-linked sales, export exposure, competitive positioning and margin sustainability. If executed, the transaction could influence capital-raising strategies across India’s life sciences and biotechnology ecosystem.